M&A Deal Summary

Mymetics Acquires Virosome Biologicals B.V.

On March 9, 2009, Mymetics acquired life science company Virosome Biologicals B.V. from Norwood Immunology for 8M EUR

Acquisition Highlights
  • This is Mymetics’ 1st transaction in the Life Science sector.
  • This is Mymetics’ 0th largest (disclosed) transaction.
  • This is Mymetics’ 1st transaction in the Netherlands.

M&A Deal Summary
Date 2009-03-09
Target Virosome Biologicals B.V.
Sector Life Science
Buyer(s) Mymetics
Sellers(s) Norwood Immunology
Deal Type Divestiture
Deal Value 8M EUR

Target

Virosome Biologicals B.V.

Groningen, Netherlands
Virosome Biologicals B.V. is developer of a proprietary vaccine delivery platform (virosome) as well as intranasal influenza and RSV vaccines.

Search 193,724 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Mymetics

Epalinges, Switzerland

website

Category Company
Founded 1990
Sector Life Science
Employees12
Revenue 2M USD (2014)
DESCRIPTION

Mymetics Corp. is a vaccine company.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Netherlands) 1 of 1
Year (2009) 1 of 1

Seller(S) 1

SELLER

Norwood Immunology

Melbourne, Australia
Category Company
Founded 2000
Sector Life Science
DESCRIPTION

Norwood Immunology Ltd. is a pharmaceutical company.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Netherlands) 1 of 1
Year (2009) 1 of 1
Mergr

Product

Company

Legal